Vulcan Value Partners LLC Purchases 11,755 Shares of IQVIA Holdings Inc. $IQV

Vulcan Value Partners LLC increased its position in IQVIA Holdings Inc. (NYSE:IQV) by 4.7% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 259,856 shares of the medical research company’s stock after acquiring an additional 11,755 shares during the period. IQVIA comprises approximately 1.5% of Vulcan Value Partners LLC’s holdings, making the stock its 15th largest position. Vulcan Value Partners LLC owned approximately 0.16% of IQVIA worth $50,209,000 at the end of the most recent quarter.

Several other institutional investors have also added to or reduced their stakes in the business. Financial Freedom LLC purchased a new position in shares of IQVIA in the first quarter worth $25,000. Ascentis Independent Advisors purchased a new stake in shares of IQVIA during the first quarter valued at $25,000. International Assets Investment Management LLC bought a new stake in IQVIA in the 4th quarter worth about $27,000. Compass Financial Management LLC bought a new stake in IQVIA in the 2nd quarter worth about $27,000. Finally, Gilpin Wealth Management LLC purchased a new position in IQVIA in the 4th quarter worth about $27,000. 89.62% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at IQVIA

In other IQVIA news, insider James G. Berkshire sold 2,668 shares of the company’s stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $261.33, for a total value of $697,228.44. Following the completion of the sale, the insider owned 10,890 shares in the company, valued at $2,845,883.70. This represents a 19.68% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider W. Richard Staub sold 5,500 shares of the firm’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $232.68, for a total value of $1,279,740.00. Following the completion of the transaction, the insider directly owned 13,312 shares in the company, valued at $3,097,436.16. This trade represents a 29.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 15,581 shares of company stock worth $3,796,021 over the last three months. 1.70% of the stock is currently owned by insiders.

Analysts Set New Price Targets

IQV has been the topic of a number of recent analyst reports. Barclays reaffirmed an “overweight” rating on shares of IQVIA in a report on Tuesday, July 28th. Morgan Stanley restated an “equal weight” rating and set a $200.00 price objective (down from $225.00) on shares of IQVIA in a research report on Wednesday, June 17th. BMO Capital Markets lifted their target price on shares of IQVIA from $210.00 to $270.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 29th. Weiss Ratings upgraded shares of IQVIA from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, July 15th. Finally, William Blair raised IQVIA to a “strong-buy” rating in a report on Tuesday, July 28th. One equities research analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $243.62.

IQVIA Stock Performance

Shares of IQV traded down $8.28 on Tuesday, reaching $259.49. The company’s stock had a trading volume of 1,381,305 shares, compared to its average volume of 1,734,320. The company has a debt-to-equity ratio of 2.18, a current ratio of 0.71 and a quick ratio of 0.71. The stock has a market capitalization of $42.71 billion, a P/E ratio of 32.19, a PEG ratio of 2.29 and a beta of 1.18. The stock’s 50 day simple moving average is $233.34 and its two-hundred day simple moving average is $194.19. IQVIA Holdings Inc. has a 12-month low of $154.50 and a 12-month high of $271.80.

IQVIA (NYSE:IQV) last announced its earnings results on Tuesday, July 28th. The medical research company reported $3.15 EPS for the quarter, beating analysts’ consensus estimates of $3.03 by $0.12. IQVIA had a net margin of 8.10% and a return on equity of 30.25%. The business had revenue of $4.37 billion during the quarter, compared to analysts’ expectations of $4.30 billion. During the same period in the prior year, the company earned $2.81 earnings per share. The firm’s revenue was up 8.7% on a year-over-year basis. IQVIA has set its FY 2026 guidance at 12.800-13.000 EPS. Research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.